enGene Holdings Inc.
ENGNDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 10, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How ENGN's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EG-70 (phase 1) | Phase 2 | Superficial Bladder Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in enGene Holdings Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in enGene Holdings Inc.'s (ENGN) pipeline across Phase 2. Its lead program is EG-70 (phase 1) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is enGene Holdings Inc.'s next FDA catalyst?→
enGene Holdings Inc.'s (ENGN) next tracked catalyst is a Earnings expected September 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENGN biotech catalysts?→
Add ENGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow enGene Holdings Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.